fluoxetine has been researched along with Anhedonia in 31 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Anhedonia: Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 7.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| "Anhedonia is a relevant symptom in depression and schizophrenia." | 5.42 | Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats. ( De Montis, MG; Ferrari, A; Gambarana, C; Pelliccia, T; Scheggi, S, 2015) |
| "The suitability of the zebrafish model of anhedonia using reserpine and fluoxetine was evaluated." | 4.31 | Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase. ( Braida, D; Dellarole, I; Morara, S; Ponzoni, L; Sala, M, 2023) |
| " We assessed fluoxetine's effects on motivated behaviors in pubescent female hamsters - anhedonia in the reward investigational preference (RIP) test as well as anxiety in the anxiety-related feeding/exploration conflict (AFEC) test." | 3.83 | Fluoxetine disrupts motivation and GABAergic signaling in adolescent female hamsters. ( DuBois, DW; Fincher, AS; Frye, GD; Henry, MM; Morgan, C; Shannonhouse, JL; Vela, AM; Wellman, PJ, 2016) |
| " Behavioral state and therapeutic efficacy of the drug treatment were assessed using sucrose preference, physical state of the coat and body weight." | 3.79 | Stress-induced anhedonia correlates with lower hippocampal serotonin transporter protein expression. ( Lei, J; Liu, G; Sun, X; Tang, M; Zhao, S, 2013) |
| " Anhedonia, brain BDNF and circulating corticosterone levels, considered endophenotypes of depression, were investigated." | 3.79 | Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. ( Alleva, E; Branchi, I; Capoccia, S; Cirulli, F; D'Andrea, I; Poggini, S; Santarelli, S, 2013) |
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 3.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| "Agmatine is an endogenous neuromodulator that has been shown to have beneficial effects in the central nervous system, including antidepressant-like effects in animals." | 1.48 | Antidepressant and pro-neurogenic effects of agmatine in a mouse model of stress induced by chronic exposure to corticosterone. ( Azevedo, DP; Brocardo, PS; Fraga, DB; Gil-Mohapel, J; Melleu, FF; Neis, VB; Olescowicz, G; Rodrigues, ALS; Rosa, PB, 2018) |
| "Vortioxetine is a novel antidepressant capable of improving depressive and cognitive symptoms associated with major depressive disorder (MDD)." | 1.48 | Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. ( Ho, CS; Ho, RC; Lu, Y; McIntyre, RS; Wang, W, 2018) |
| "Harmine treatment (20mg/kg) prevented the reductions in brain-derived neurotrophic factor (BDNF) protein levels and hippocampal neurogenesis induced by CUS." | 1.46 | Harmine produces antidepressant-like effects via restoration of astrocytic functions. ( Chen, X; Gong, Y; Huang, C; Ling, Y; Liu, F; Tong, L; Wang, P; Wu, J; Zhu, L, 2017) |
| "Anhedonia is a relevant symptom in depression and schizophrenia." | 1.42 | Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats. ( De Montis, MG; Ferrari, A; Gambarana, C; Pelliccia, T; Scheggi, S, 2015) |
| "Anhedonia was evaluated using the sucrose preference test (SPT), and behavioural despair was evaluated using the forced swim test (FST) and tail suspension test (TST)." | 1.42 | Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression. ( Frey, BN; Nashed, MG; Seidlitz, EP; Singh, G, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 26 (83.87) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Ramírez-Rodríguez, GB | 1 |
| Vega-Rivera, NM | 1 |
| Meneses-San Juan, D | 1 |
| Ortiz-López, L | 1 |
| Estrada-Camarena, EM | 1 |
| Flores-Ramos, M | 1 |
| Braida, D | 1 |
| Ponzoni, L | 1 |
| Dellarole, I | 1 |
| Morara, S | 1 |
| Sala, M | 1 |
| Orrico-Sanchez, A | 2 |
| Guiard, BP | 2 |
| Manta, S | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Louis, F | 2 |
| Paccard, A | 1 |
| Gruszczynski, C | 2 |
| Betancur, C | 1 |
| Vialou, V | 2 |
| Gautron, S | 2 |
| Chausset-Boissarie, L | 1 |
| Alves de Sousa, R | 1 |
| Coutens, B | 1 |
| Rezai Amin, S | 1 |
| Hessani, A | 1 |
| Dansette, PM | 1 |
| Zornoza, T | 1 |
| Giros, B | 1 |
| Acher, F | 1 |
| Pietrancosta, N | 1 |
| Ramos-Hryb, AB | 1 |
| Ramirez, MF | 1 |
| Lino-de-Oliveira, C | 1 |
| Pagani, MR | 1 |
| Liu, F | 1 |
| Wu, J | 1 |
| Gong, Y | 1 |
| Wang, P | 1 |
| Zhu, L | 1 |
| Tong, L | 1 |
| Chen, X | 1 |
| Ling, Y | 1 |
| Huang, C | 1 |
| Olescowicz, G | 1 |
| Neis, VB | 2 |
| Fraga, DB | 1 |
| Rosa, PB | 1 |
| Azevedo, DP | 1 |
| Melleu, FF | 1 |
| Brocardo, PS | 1 |
| Gil-Mohapel, J | 1 |
| Rodrigues, ALS | 1 |
| Lu, Y | 1 |
| Ho, CS | 1 |
| McIntyre, RS | 1 |
| Wang, W | 1 |
| Ho, RC | 1 |
| Poggini, S | 2 |
| Golia, MT | 1 |
| Alboni, S | 1 |
| Milior, G | 1 |
| Sciarria, LP | 1 |
| Viglione, A | 1 |
| Matte Bon, G | 1 |
| Brunello, N | 1 |
| Puglisi-Allegra, S | 1 |
| Limatola, C | 1 |
| Maggi, L | 1 |
| Branchi, I | 2 |
| Tang, M | 1 |
| Lei, J | 1 |
| Sun, X | 1 |
| Liu, G | 1 |
| Zhao, S | 1 |
| Santarelli, S | 1 |
| Capoccia, S | 1 |
| D'Andrea, I | 1 |
| Cirulli, F | 1 |
| Alleva, E | 1 |
| Morozova, AY | 1 |
| Zubkov, EA | 1 |
| Storozheva, ZI | 1 |
| Kekelidze, ZI | 1 |
| Chekhonin, VP | 1 |
| Bessa, JM | 1 |
| Morais, M | 1 |
| Marques, F | 1 |
| Pinto, L | 1 |
| Palha, JA | 1 |
| Almeida, OF | 1 |
| Sousa, N | 1 |
| El Yacoubi, M | 2 |
| Rappeneau, V | 1 |
| Champion, E | 1 |
| Malleret, G | 1 |
| Vaugeois, JM | 2 |
| Der-Avakian, A | 1 |
| Mazei-Robison, MS | 1 |
| Kesby, JP | 1 |
| Nestler, EJ | 1 |
| Markou, A | 1 |
| Li, Y | 3 |
| Wang, H | 1 |
| Wang, X | 2 |
| Liu, Z | 1 |
| Wan, Q | 1 |
| Wang, G | 1 |
| Yang, C | 1 |
| Guo, X | 1 |
| Wang, GH | 1 |
| Wang, HL | 1 |
| Liu, ZC | 1 |
| Liu, H | 1 |
| Zhu, ZX | 1 |
| Pan, Y | 2 |
| Chen, XY | 1 |
| Zhang, QY | 2 |
| Kong, LD | 2 |
| Scheggi, S | 1 |
| Pelliccia, T | 1 |
| Ferrari, A | 1 |
| De Montis, MG | 1 |
| Gambarana, C | 1 |
| Nashed, MG | 1 |
| Seidlitz, EP | 1 |
| Frey, BN | 1 |
| Singh, G | 1 |
| Meng, X | 1 |
| Shen, F | 1 |
| Li, C | 1 |
| Shannonhouse, JL | 1 |
| DuBois, DW | 1 |
| Fincher, AS | 1 |
| Vela, AM | 1 |
| Henry, MM | 1 |
| Wellman, PJ | 1 |
| Frye, GD | 1 |
| Morgan, C | 1 |
| Amigó, J | 1 |
| Díaz, A | 1 |
| Pilar-Cuéllar, F | 1 |
| Vidal, R | 1 |
| Martín, A | 1 |
| Compan, V | 1 |
| Pazos, A | 1 |
| Castro, E | 1 |
| Xia, M | 1 |
| Yang, L | 1 |
| Sun, G | 1 |
| Qi, S | 1 |
| Li, B | 2 |
| Popa, D | 1 |
| Martin, B | 1 |
| Zimmer, L | 1 |
| Hamon, M | 1 |
| Adrien, J | 1 |
| Light, SN | 1 |
| Heller, AS | 1 |
| Johnstone, T | 1 |
| Kolden, GG | 1 |
| Peterson, MJ | 1 |
| Kalin, NH | 1 |
| Davidson, RJ | 1 |
| Pal, A | 1 |
| Nayak, S | 1 |
| Sahu, PK | 1 |
| Swain, T | 1 |
| Hong, Y | 1 |
| Dong, L | 1 |
| Wang, B | 1 |
| Cai, L | 1 |
| Jiang, N | 1 |
| Peng, L | 1 |
| Freitas, AE | 1 |
| Machado, DG | 1 |
| Budni, J | 1 |
| Balen, GO | 1 |
| Lopes, MW | 1 |
| de Souza, LF | 1 |
| Dafre, AL | 1 |
| Leal, RB | 1 |
| Rodrigues, AL | 1 |
| Ledo, JH | 1 |
| Azevedo, EP | 1 |
| Clarke, JR | 1 |
| Ribeiro, FC | 1 |
| Figueiredo, CP | 1 |
| Foguel, D | 1 |
| De Felice, FG | 1 |
| Ferreira, ST | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine[NCT00909155] | 50 participants (Actual) | Interventional | 2002-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Depressed participants were scanned while viewing a sequence of positive and negative images; they were instructed to enhance or supress their emotional response to the image or to continue to attend. To examine brain function when regulating negative affect, we created contrast maps for each participant at all 3 time points by subtracting the attend condition from the suppress condition in response to negative stimuli. Data from all 3 scan sessions were used to assess treatment-induced change in brain activity when regulating emotion. Analyses examining change using difference scores (end vs. starting points), we subtracted initial HAMD score from final HAMD score. For fMRI analyses, in a voxelwise manner, we subtracted initial negative suppress vs attend from final negative suppress vs attend.~Control subjects were not depressed, repeat scans to assess change were not completed.~Reported results are from BA10, one of our areas of interest." (NCT00909155)
Timeframe: At study entry, 2 months and end of study (6 months)
| Intervention | fMRI signal change (Mean) |
|---|---|
| Depressed; Venlafaxine Treatment | -0.042666667 |
| Depressed; Fluoxetine Treatment | 0.0414 |
"Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).~Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety)." (NCT00909155)
Timeframe: Study entry, 2 months, and at end of study (6 mos)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| HAMD T0 | HAMA T0 | HAMD 2months | HAMA 2months | HAMD 6months | HAMA 6months | |
| Control (Non-psychiatric Subjects) | 1 | NA | 1.25 | NA | 1.64 | NA |
| Currently Depressed Subjects: Fluoxetine | 21.36 | 15.57 | 10.15 | 8.54 | 7.33 | 5.89 |
| Currently Depressed Subjects: Venlafaxine | 20.07 | 14.07 | 8.86 | 7.5 | 5 | 4.25 |
1 trial available for fluoxetine and Anhedonia
| Article | Year |
|---|---|
Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder.
Topics: Adult; Anhedonia; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met | 2011 |
30 other studies available for fluoxetine and Anhedonia
| Article | Year |
|---|---|
Short Daily Exposure to Environmental Enrichment, Fluoxetine, or Their Combination Reverses Deterioration of the Coat and Anhedonia Behaviors with Differential Effects on Hippocampal Neurogenesis in Chronically Stressed Mice.
Topics: Anhedonia; Animals; Behavior, Animal; Calbindin 2; Cell Proliferation; Doublecortin Protein; Environ | 2021 |
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase.
Topics: Anhedonia; Animals; Calcitonin Gene-Related Peptide; Fluoxetine; Nicotine; Reserpine; Substance With | 2023 |
Organic cation transporter 2 contributes to SSRI antidepressant efficacy by controlling tryptophan availability in the brain.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain; Corticosterone; Depressive Disorder, Major; Fluoxe | 2023 |
Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Anxiety; Depression; Disease Models, Animal; Fluoxetine; | 2020 |
Stress-mediated hyperactivity and anhedonia resistant to diazepam and fluoxetine in
Topics: Anhedonia; Animals; Diazepam; Disease Models, Animal; Drosophila; Fluoxetine; Stress, Psychological | 2021 |
Harmine produces antidepressant-like effects via restoration of astrocytic functions.
Topics: Anhedonia; Animals; Antidepressive Agents; Astrocytes; Brain-Derived Neurotrophic Factor; Chronic Di | 2017 |
Antidepressant and pro-neurogenic effects of agmatine in a mouse model of stress induced by chronic exposure to corticosterone.
Topics: Agmatine; Anhedonia; Animals; Antidepressive Agents; Cell Proliferation; Corticosterone; Depressive | 2018 |
Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, M | 2018 |
Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus.
Topics: Anhedonia; Animals; Antidepressive Agents; Depressive Disorder; Disease Models, Animal; Drug Therapy | 2019 |
Stress-induced anhedonia correlates with lower hippocampal serotonin transporter protein expression.
Topics: Analysis of Variance; Anhedonia; Animals; Body Weight; Disease Models, Animal; Fluoxetine; Food Pref | 2013 |
Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Brain; Brain-Derived Neurotrophic Facto | 2013 |
Effect of ultrasonic irradiation on the development of symptoms of depression and anxiety in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Disease Models, An | 2013 |
Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens.
Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Fluoxetine; Hypertrophy; Imipramine; Ma | 2013 |
The H/Rouen mouse model displays depression-like and anxiety-like behaviors.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Anxiety; Comorbidity; Depressive Disor | 2013 |
Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Desipramine; Electric | 2014 |
Differential expression of hippocampal EphA4 and ephrinA3 in anhedonic-like behavior, stress resilience, and antidepressant drug treatment after chronic unpredicted mild stress.
Topics: Anhedonia; Animals; Antidepressive Agents; Ephrin-A3; Fluoxetine; Hippocampus; Male; Rats, Sprague-D | 2014 |
Changes in tau phosphorylation levels in the hippocampus and frontal cortex following chronic stress.
Topics: Alzheimer Disease; Analysis of Variance; Anhedonia; Animals; Antidepressive Agents, Second-Generatio | 2014 |
Microglial NLRP3 inflammasome activation mediates IL-1β-related inflammation in prefrontal cortex of depressive rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Calcium-Binding Proteins; Carrier Proteins; Chronic Disea | 2014 |
Impramine, fluoxetine and clozapine differently affected reactivity to positive and negative stimuli in a model of motivational anhedonia in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Antipsychotic Agents; Clozapine; Dietary Sucrose; Disease | 2015 |
Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Cell Line, Tumor; Corticosterone; Dend | 2015 |
Depression-like behaviors in tree shrews and comparison of the effects of treatment with fluoxetine and carbetocin.
Topics: Anhedonia; Animals; Antidepressive Agents; Depression; Electroshock; Fluoxetine; Helplessness, Learn | 2016 |
Fluoxetine disrupts motivation and GABAergic signaling in adolescent female hamsters.
Topics: Anhedonia; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Conflict, Psychological; Cricetinae; | 2016 |
The absence of 5-HT
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Anhedonia; Animals; Antidepressive Agents, Second-Generation | 2016 |
Mechanism of depression as a risk factor in the development of Alzheimer's disease: the function of AQP4 and the glymphatic system.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anhedonia; Animals; Antidepressive Agents; Aquaporin 4; Br | 2017 |
Genetic association between helpless trait and depression-related phenotypes: evidence from crossbreeding studies with H/Rouen and NH/Rouen mice.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Depressive Disorder; Dietary Sucrose; | 2012 |
Piperine protects epilepsy associated depression: a study on role of monoamines.
Topics: Alkaloids; Anhedonia; Animals; Anticonvulsants; Behavior, Animal; Benzodioxoles; Biogenic Monoamines | 2011 |
Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system.
Topics: Anhedonia; Animals; Antidepressive Agents; Arcuate Nucleus of Hypothalamus; Chronic Disease; Cortico | 2013 |
Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stress-induced anhedonia.
Topics: Anhedonia; Animals; Base Sequence; Brain; DNA Primers; Female; Flow Cytometry; Fluoxetine; Gene Expr | 2012 |
Fluoxetine modulates hippocampal cell signaling pathways implicated in neuroplasticity in olfactory bulbectomized mice.
Topics: Analysis of Variance; Anhedonia; Animals; Antidepressive Agents, Second-Generation; Brain-Derived Ne | 2013 |
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anhedonia; Animals; Brain Chemistry; Cognition Disorders; | 2013 |